Leader in innovation

Théa, a company that focuses on its R&D

Laboratoires Théa have defined a development strategy based on three key areas:

Innovative delivery systems.
The deployment of new active ingredients for ophthalmology.
The improvement of existing products through formulation.

In just 30 years, Théa's R&D has generated 30 therapeutic innovations, offering major advancements in the fields of glaucoma, allergies, inflammation, infections, and dry eye.

These innovations are also breaking ground in new therapeutic areas such as eyelid hygiene, antibiotic therapy, intracameral mydriasis, and ocular nutrition.

Consult all our areas of expertise

Formulation and "preservative-free" solutions

Théa: more than just active ingredients.

Specialized in ophthalmology, we innovate in formulation and administration methods. Our wide range of products (single-dose eye drops, ointments, gels, injectables, etc.) addresses the specific needs of each patient.

Théa is also a pioneer in preservative-free forms and is the originator of the first multi-dose bottle capable of dispensing preservative-free eye drops: the ABAK®, with one bottle being distributed every second worldwide.

Learn more about “preservative-free” solutions

Collaborating with the best

The Théa group is 100% dedicated to ophthalmology and offers a unique approach based on collaboration.
While its R&D is carried out by a highly specialized internal team, Théa relies on an ecosystem of expert partners in their fields:

Strong partnerships: We collaborate with renowned institutions and support researchers in their projects.
Made in Europe manufacturing: Our products are manufactured at state-of-the-art facilities in France and Europe, adhering to the most rigorous standards and norms.
Local and international economic impact: These long-term collaborations create numerous jobs for our partners.

Théa benefits from global expertise and accelerates the development of new treatments. Our collaborative model, combined with high-quality production, makes Théa a major player in ocular health innovation.

Théa Open Innovation, a structure dedicated to open innovation

Founded in 2019 by Jean-Frédéric Chibret, Théa Open Innovation (TOI) is a sister company to Laboratoires Théa, designed to implement innovative solutions in ocular health.

TOI’s mission is to:

Attract external expertise.
Establish new collaborations.
Foster the emergence of innovative solutions for the treatment of ocular diseases.

In practice, Théa Open Innovation continually fuels Théa's R&D branch with new projects, particularly in rare diseases and e-health solutions.

Learn more about Théa Open Innovation